New first-in-human study explores immune-engineered cell therapy approach for type 1 diabetes

MedicalXpress | Jul 10, 2026

New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.